Medicare GLP-1 Coverage (2026)
The $50 Cap & CMS Bridge Program
2026 marks a monumental shift in how Medicare handles anti-obesity medications (AOMs). With new legislation capping out-of-pocket costs and expanding eligibility, millions of seniors now have access to GLP-1 therapies.
2026 Rollout Timeline
January 1, 2026
The new $2,000 annual out-of-pocket cap for Medicare Part D takes full effect.
April 2026
CMS officially integrates "Obesity as a primary condition" for Wegovy and Zepbound coverage under the new Bridge Program.
July 2026
The $50 monthly co-pay cap for preferred GLP-1 tier medications begins for eligible enrollees.
Eligibility vs. Coverage (2026)
| Medication | Indication Required for Medicare | Estimated Monthly Cost (Part D) |
|---|---|---|
| Ozempic | Type 2 Diabetes | $0 - $50 (Depending on plan) |
| Mounjaro | Type 2 Diabetes | $0 - $50 (Depending on plan) |
| Wegovy | Cardiovascular Risk + Obesity | Capped at $50/mo (Bridge Program) |
| Zepbound | Obesity (BMI > 30 with comorbidities) | Capped at $50/mo (Bridge Program) |
Note: Pure cosmetic weight loss remains excluded. A documented comorbidity is required for Wegovy/Zepbound.
How the $50 Cap Works
Prior to 2026, patients on Medicare Part D often fell into the "donut hole," paying hundreds of dollars monthly for GLP-1s. The new legislation eliminates this gap.
If you are prescribed an FDA-approved GLP-1 for a covered indication, your maximum out-of-pocket cost is legally capped at $50 per month, contributing to a strict $2,000 annual maximum for all Part D drugs.
Step Therapy Alert
Many Medicare Advantage (Part C) plans still require "Step Therapy"—meaning you may have to try and fail a cheaper medication (like Qsymia or Contrave) before they will approve Zepbound or Wegovy.
Steps to Get Approved
Check Your BMI: You must have a BMI > 30, or > 27 with a weight-related condition (e.g., hypertension).
Document Previous Attempts: Have your doctor document previous weight-loss programs you have tried.
Submit a Prior Authorization (PA): Your doctor must submit a PA explicitly citing the new 2026 CMS guidelines.
Appeal if Denied: Up to 40% of initial PAs are denied due to paperwork errors. Always file an appeal.
Guide FAQs
No. The law still prohibits Medicare from covering drugs strictly for cosmetic weight loss. However, the 2026 rules broadened the definition of "medical necessity" to include obesity when paired with a comorbidity like heart disease or sleep apnea.
It is a temporary funding mechanism designed to subsidize the cost of high-tier anti-obesity medications until generic or cheaper alternatives enter the market.
Track Your Health Metrics for Medicare PA
Shotlee allows you to easily export your weight loss progress and BMI history to share with your doctor for Prior Authorization renewals.
🚀 Use Shotlee for Free